---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-277962"
form_type: "8-K"
ticker: null
cik: "0001492674"
company_name: "T2 Biosystems, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:32:33.482987+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# T2 Biosystems receives Nasdaq delisting notice; hearing set for Jan 9, 2025

## Summary
- Received Nasdaq letter on Dec 12, 2024 for bid price below $1.00 for 30 consecutive days under Rule 5550(a)(2).
- Previously on Nov 7, 2024, received notice of market value of listed securities below $35M (Rule 5550(b)(2)).
- Staff issued delist determination; company requested hearing and paid $20k fee, stay granted.
- Hearing scheduled for Jan 9, 2025; stock remains listed pending panel decision.
- No assurance of continued listing; failure to comply could lead to delisting.

## SEC filing metadata
- accession: 0001193125-24-277962
- form_type: 8-K
- cik: 0001492674
- company_name: T2 Biosystems, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492674/000119312524277962/0001193125-24-277962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492674/000119312524277962/d849479d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-277962
- JSON: https://secwatch.observer/filing/0001193125-24-277962.json
- Plain text: https://secwatch.observer/filing/0001193125-24-277962.txt

## Key facts
- Listing & Compliance Notices
  T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: November 7, 2024, the Company received a separate letter from Nasdaq indicating that the Company’s market value of its listed securities has been below the minimum $35,000,000 required for continued listing on the Nasdaq Capital Market, as set forth in Listing Rule 5550(b)(2) for the previous thirty consecutive trading days. In accordance with the terms of the previously imposed “Mandatory Panel Monitor” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), the Nasdaq Listing Qualifications Staff (the “Staff”) did not grant the Company a grace period but rather issued a delist determin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312524277962/0001193125-24-277962-index.htm
- Listing & Compliance Notices
  T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 12, 2024, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on November 7, 2024, the Company received a separate letter from Nasdaq indicating that the Company’s market value of its listed securities has been below the minimum $35,000,000 required for continued listing on the Nasdaq Cap
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312524277962/0001193125-24-277962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.